{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:27:29Z","timestamp":1780597649411,"version":"3.54.1"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10072-024-07970-2","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T06:01:04Z","timestamp":1736143264000},"page":"1509-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease"],"prefix":"10.1007","volume":"46","author":[{"given":"Amir","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevika","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-2749","authenticated-orcid":false,"given":"Pankaj","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"1","key":"7970_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck J, Bower J, Roberts E, Ritz B, Ross G, Abbott R, Savica R, Van Den Eeden S, Willis A (2018) Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinson\u2019s disease 4(1):21","journal-title":"NPJ Parkinson's disease"},{"issue":"11","key":"7970_CR2","first-page":"24","volume":"49","author":"VM Vacca Jr","year":"2019","unstructured":"Vacca VM Jr (2019) Parkinson disease: Enhance nursing knowledge. Nursing 2022 49(11):24\u201332","journal-title":"Nursing 2022"},{"key":"7970_CR3","doi-asserted-by":"crossref","unstructured":"Alissa M, Lones MA, Cosgrove J, Alty JE, Jamieson S, Smith SL, Vallejo M (2022) Parkinson\u2019s disease diagnosis using convolutional neural networks and figure-copying tasks. Neural Comput Appl1\u201321","DOI":"10.1007\/s00521-021-06469-7"},{"issue":"10291","key":"7970_CR4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. The Lancet 397(10291):2284\u20132303","journal-title":"The Lancet"},{"key":"7970_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0099-z","volume":"6","author":"P Maiti","year":"2017","unstructured":"Maiti P, Manna J, Dunbar GL (2017) Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments. Transl Neurodegener 6:1\u201335","journal-title":"Transl Neurodegener"},{"issue":"10","key":"7970_CR6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1101\/lm.032029.113","volume":"20","author":"N Solari","year":"2013","unstructured":"Solari N, Bonito-Oliva A, Fisone G, Brambilla R (2013) Understanding cognitive deficits in Parkinson\u2019s disease: lessons from preclinical animal models. Learn Mem 20(10):592\u2013600","journal-title":"Learn Mem"},{"issue":"6","key":"7970_CR7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S (2003) Parkinson\u2019s disease: mechanisms and models. Neuron 39(6):889\u2013909","journal-title":"Neuron"},{"issue":"3","key":"7970_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","volume":"6","author":"GE Alexander","year":"2004","unstructured":"Alexander GE (2004) Biology of Parkinson\u2019s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 6(3):259\u2013280","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"7970_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","volume":"90","author":"PP Michel","year":"2016","unstructured":"Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90(4):675\u2013691","journal-title":"Neuron"},{"key":"7970_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-082410-101440","volume":"12","author":"I Martin","year":"2011","unstructured":"Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson\u2019s disease. Annu Rev Genomics Hum Genet 12:301\u2013325","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"7970_CR11","doi-asserted-by":"crossref","unstructured":"Chauhan A, Jeans AF (2015) Is Parkinson\u2019s disease truly a prion-like disorder? An appraisal of current evidence. Neurol Res Int 2015","DOI":"10.1155\/2015\/345285"},{"issue":"1","key":"7970_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","volume":"86","author":"CA Davie","year":"2008","unstructured":"Davie CA (2008) A review of Parkinson\u2019s disease. Br Med Bull 86(1):109\u2013127","journal-title":"Br Med Bull"},{"issue":"4","key":"7970_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/mdc3.12062","volume":"1","author":"LM Chahine","year":"2014","unstructured":"Chahine LM, Stern MB (2014) Characterizing premotor Parkinson\u2019s disease: clinical features and objective markers. Movement Disord Clin Pract 1(4):299\u2013306","journal-title":"Movement Disord Clin Pract"},{"key":"7970_CR14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 139:318\u2013324","journal-title":"J Neurochem"},{"issue":"5","key":"7970_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14737175.2015.1038244","volume":"15","author":"AQ Rana","year":"2015","unstructured":"Rana AQ, Ahmed US, Chaudry ZM, Vasan S (2015) Parkinson\u2019s disease: a review of non-motor symptoms. Expert Rev Neurother 15(5):549\u2013562","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"7970_CR16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB (2018) Neurotransmitter deficits from frontotemporal lobar degeneration. Brain 141(5):1263\u20131285","journal-title":"Brain"},{"issue":"4","key":"7970_CR17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368\u2013376","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"7970_CR18","first-page":"129","volume":"103","author":"P Santens","year":"2003","unstructured":"Santens P, Boon P, Van Roost D, Caemaert J (2003) The pathophysiology of motors symptoms in Parkinson\u2019s disease. Acta Neurol Belg 103(3):129\u2013134","journal-title":"Acta Neurol Belg"},{"key":"7970_CR19","doi-asserted-by":"crossref","unstructured":"Goedert M, Jakes R, Anthony Crowther R, Grazia Spillantini M (2001) Parkinson's disease, dementia with lewy bodies, and multiple system atrophy as \u03b1-synucleinopathies. Parkinson's Disease: Methods And Protocols 33\u201359.","DOI":"10.1385\/1-59259-142-6:33"},{"issue":"1","key":"7970_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA, Korczyn AD (2018) Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease? BMC Med 16(1):1\u201316","journal-title":"BMC Med"},{"key":"7970_CR21","doi-asserted-by":"crossref","unstructured":"Riederer P, Nagatsu T, Youdim MB, Wulf M, Dijkstra JM, Sian-Huelsmann J (2023) Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson\u2019s disease. J Neural Transmission 1\u201320.","DOI":"10.1007\/s00702-023-02630-9"},{"issue":"11","key":"7970_CR22","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","volume":"71","author":"L Pan","year":"2021","unstructured":"Pan L, Meng L, He M, Zhang Z (2021) Tau in the Pathophysiology of Parkinson\u2019s Disease. J Mol Neurosci 71(11):2179\u20132191. https:\/\/doi.org\/10.1007\/s12031-020-01776-5","journal-title":"J Mol Neurosci"},{"key":"7970_CR23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fneur.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J (2018) Tau pathology in Parkinson\u2019s disease. Front Neurol 9:809","journal-title":"Front Neurol"},{"key":"7970_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnagi.2019.00256","volume":"11","author":"NI Trushina","year":"2019","unstructured":"Trushina NI, Bakota L, Mulkidjanian AY, Brandt R (2019) The evolution of tau phosphorylation and interactions. Front Aging Neurosci 11:256","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"7970_CR25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/emmm.200900024","volume":"1","author":"E Deas","year":"2009","unstructured":"Deas E, Plun-Favreau H, Wood NW (2009) PINK1 function in health and disease. EMBO Mol Med 1(3):152\u2013165","journal-title":"EMBO Mol Med"},{"issue":"3","key":"7970_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ane.12616","volume":"135","author":"M Ferreira","year":"2017","unstructured":"Ferreira M, Massano J (2017) An updated review of Parkinson\u2019s disease genetics and clinicopathological correlations. Acta Neurol Scand 135(3):273\u2013284","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"7970_CR27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3988\/jcn.2009.5.4.192","volume":"5","author":"J-H Seo","year":"2009","unstructured":"Seo J-H, Song S-K, Lee PH (2009) A novel PANK2 mutation in a patient with atypical pantothenate-kinase-associated neurodegeneration presenting with adult-onset parkinsonism. J Clin Neurol 5(4):192\u2013194","journal-title":"J Clin Neurol"},{"issue":"6","key":"7970_CR28","doi-asserted-by":"crossref","first-page":"e67506","DOI":"10.1371\/journal.pone.0067506","volume":"8","author":"W-EJ Tseng","year":"2013","unstructured":"Tseng W-EJ, Chen C-M, Chen Y-C, Yi Z, Tan E-K, Wu Y-R (2013) Genetic variations of GAK in two Chinese Parkinson\u2019s disease populations: a case-control study. PLoS ONE 8(6):e67506","journal-title":"PLoS ONE"},{"issue":"3","key":"7970_CR29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(08)70022-X","volume":"7","author":"S Camargos","year":"2008","unstructured":"Camargos S, Scholz S, Sim\u00f3n-S\u00e1nchez J, Pais\u00e1n-Ruiz C, Lewis P, Hernandez D, Ding J, Gibbs JR, Cookson MR, Bras J (2008) DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. The Lancet Neurology 7(3):207\u2013215","journal-title":"The Lancet Neurology"},{"issue":"7","key":"7970_CR30","doi-asserted-by":"crossref","first-page":"e11468","DOI":"10.1371\/journal.pone.0011468","volume":"5","author":"A Hiona","year":"2010","unstructured":"Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, Hofer T, Someya S, Miyakawa T, Nakayama C, Samhan-Arias AK (2010) Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PLoS ONE 5(7):e11468","journal-title":"PLoS ONE"},{"issue":"1","key":"7970_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s43042-021-00208-2","volume":"22","author":"S Ganesan","year":"2021","unstructured":"Ganesan S, Parvathi VD (2021) Deconstructing the molecular genetics behind the PINK1\/Parkin axis in Parkinson\u2019s disease using Drosophila melanogaster as a model organism. Egyptian J Med Human Genetics 22(1):86. https:\/\/doi.org\/10.1186\/s43042-021-00208-2","journal-title":"Egyptian J Med Human Genetics"},{"key":"7970_CR32","unstructured":"Saunders-Pullman R, Raymond D, Elango S (2023) LRRK2 Parkinson disease. GeneReviews\u00ae[Internet]."},{"issue":"4","key":"7970_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10048-009-0187-z","volume":"10","author":"IF Mata","year":"2009","unstructured":"Mata IF, Hutter CM, Gonz\u00e1lez-Fern\u00e1ndez MC, de Pancorbo MM, Lezcano E, Huerta C, Blazquez M, Ribacoba R, Guisasola LM, Salvador C et al (2009) Lrrk2 R1441G-related Parkinson\u2019s disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics 10(4):347\u2013353. https:\/\/doi.org\/10.1007\/s10048-009-0187-z","journal-title":"Neurogenetics"},{"issue":"4","key":"7970_CR34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","volume":"40","author":"BJ Ryan","year":"2015","unstructured":"Ryan BJ, Hoek S, Fon EA, Wade-Martins R (2015) Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease. Trends Biochem Sci 40(4):200\u2013210","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"7970_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00439-011-1133-3","volume":"131","author":"N-N Li","year":"2012","unstructured":"Li N-N, Chang X-L, Mao X-Y, Zhang J-H, Zhao D-M, Tan E-K, Peng R (2012) GWAS-linked GAK locus in Parkinson\u2019s disease in Han Chinese and meta-analysis. Hum Genet 131(7):1089\u20131093. https:\/\/doi.org\/10.1007\/s00439-011-1133-3","journal-title":"Hum Genet"},{"issue":"305","key":"7970_CR36","doi-asserted-by":"crossref","first-page":"305ps320","DOI":"10.1126\/scitranslmed.aaa8280","volume":"7","author":"MP van der Brug","year":"2015","unstructured":"van der Brug MP, Singleton A, Gasser T, Lewis PA (2015) Parkinson\u2019s disease: from human genetics to clinical trials. Sci Transl Med 7(305):305ps320-305ps320","journal-title":"Sci Transl Med"},{"issue":"12","key":"7970_CR37","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/mds.25981","volume":"29","author":"M Zech","year":"2014","unstructured":"Zech M, Castrop F, Schormair B, Jochim A, Wieland T, Gross N, Lichtner P, Peters A, Gieger C, Meitinger T (2014) DYT16 revisited: exome sequencing identifies PRKRA mutations in a European dystonia family. Mov Disord 29(12):1504\u20131510","journal-title":"Mov Disord"},{"issue":"5","key":"7970_CR38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1073\/pnas.0607621104","volume":"104","author":"R Leonardi","year":"2007","unstructured":"Leonardi R, Rock CO, Jackowski S, Zhang Y-M (2007) Activation of human mitochondrial pantothenate kinase 2 by palmitoylcarnitine. Proc Natl Acad Sci 104(5):1494\u20131499","journal-title":"Proc Natl Acad Sci"},{"key":"7970_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00401-020-02202-1","volume":"141","author":"J Br\u00e1s","year":"2021","unstructured":"Br\u00e1s J, Gibbons E, Guerreiro R (2021) Genetics of synucleins in neurodegenerative diseases. Acta Neuropathol 141:471\u2013490","journal-title":"Acta Neuropathol"},{"issue":"8","key":"7970_CR40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/life11080804","volume":"11","author":"L Magistrelli","year":"2021","unstructured":"Magistrelli L, Contaldi E, Comi C (2021) The impact of SNCA variations and its product alpha-synuclein on non-motor features of parkinson\u2019s disease. Life 11(8):804","journal-title":"Life"},{"issue":"2","key":"7970_CR41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 16(2):97\u2013107","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"7970_CR42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nsmb.2865","volume":"21","author":"KD Warner","year":"2014","unstructured":"Warner KD, Chen MC, Song W, Strack RL, Thorn A, Jaffrey SR, Ferr\u00e9-D\u2019Amar\u00e9 AR (2014) Structural basis for activity of highly efficient RNA mimics of green fluorescent protein. Nat Struct Mol Biol 21(8):658\u2013663","journal-title":"Nat Struct Mol Biol"},{"key":"7970_CR43","doi-asserted-by":"crossref","first-page":"777942","DOI":"10.3389\/fgene.2021.777942","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Zhang C, Ji Y (2021) Association of GAK rs1564282 With Susceptibility to Parkinson\u2019s Disease in Chinese Populations. Front Genet 12:777942","journal-title":"Front Genet"},{"issue":"8","key":"7970_CR44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp-2012-302402","volume":"83","author":"A McNeill","year":"2012","unstructured":"McNeill A, Duran R, Hughes DA, Mehta A, Schapira AH (2012) A clinical and family history study of Parkinson\u2019s disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 83(8):853\u2013854","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"7970_CR45","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A (2012) Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(1):a008888","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"7970_CR46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrn2935","volume":"11","author":"MR Cookson","year":"2010","unstructured":"Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. Nat Rev Neurosci 11(12):791\u2013797","journal-title":"Nat Rev Neurosci"},{"key":"7970_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04469-x","author":"DS Kathiresan","year":"2024","unstructured":"Kathiresan DS, Balasubramani R, Marudhachalam K, Jaiswal P, Ramesh N, Sureshbabu SG, Puthamohan VM, Vijayan M (2024) Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-024-04469-x","journal-title":"Mol Neurobiol"},{"issue":"1","key":"7970_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1326-4-24","volume":"4","author":"KA Malkus","year":"2009","unstructured":"Malkus KA, Tsika E, Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson\u2019s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4(1):24. https:\/\/doi.org\/10.1186\/1750-1326-4-24","journal-title":"Mol Neurodegener"},{"key":"7970_CR49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","volume":"298","author":"AB West","year":"2017","unstructured":"West AB (2017) Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol 298:236\u2013245","journal-title":"Exp Neurol"},{"issue":"6","key":"7970_CR50","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jnr.21949","volume":"87","author":"PN Gandhi","year":"2009","unstructured":"Gandhi PN, Chen SG, Wilson-Delfosse AL (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson\u2019s disease. J Neurosci Res 87(6):1283\u20131295","journal-title":"J Neurosci Res"},{"issue":"4","key":"7970_CR51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/01677063.2011.627072","volume":"25","author":"RE Drolet","year":"2011","unstructured":"Drolet RE, Sanders JM, Kern JT (2011) Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. J Neurogenet 25(4):140\u2013151","journal-title":"J Neurogenet"},{"issue":"22","key":"7970_CR52","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1111\/j.1742-4658.2009.07344.x","volume":"276","author":"U Kumari","year":"2009","unstructured":"Kumari U, Tan E (2009) LRRK2 in Parkinson\u2019s disease: genetic and clinical studies from patients. FEBS J 276(22):6455\u20136463","journal-title":"FEBS J"},{"key":"7970_CR53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnagi.2019.00013","volume":"11","author":"L Shu","year":"2019","unstructured":"Shu L, Zhang Y, Sun Q, Pan H, Tang B (2019) A comprehensive analysis of population differences in LRRK2 variant distribution in Parkinson\u2019s disease. Front Aging Neurosci 11:13","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"7970_CR54","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nn.2349","volume":"12","author":"Y Li","year":"2009","unstructured":"Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S (2009) Mutant LRRK2 R1441G BAC transgenic mice recapitulate cardinal features of Parkinson\u2019s disease. Nat Neurosci 12(7):826\u2013828","journal-title":"Nat Neurosci"},{"issue":"451","key":"7970_CR55","doi-asserted-by":"crossref","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","volume":"10","author":"R Di Maio","year":"2018","unstructured":"Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA (2018) LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med 10(451):eaar5429","journal-title":"Sci Transl Med"},{"issue":"565","key":"7970_CR56","doi-asserted-by":"crossref","first-page":"eaay0399","DOI":"10.1126\/scitranslmed.aay0399","volume":"12","author":"C Kim","year":"2020","unstructured":"Kim C, Beilina A, Smith N, Li Y, Kim M, Kumaran R, Kaganovich A, Mamais A, Adame A, Iba M (2020) LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med 12(565):eaay0399","journal-title":"Sci Transl Med"},{"key":"7970_CR57","doi-asserted-by":"crossref","first-page":"104626","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"EM Rocha","year":"2020","unstructured":"Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, Smith SM, Keeney MT, Di Maio R, Kofler J (2020) LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol Dis 134:104626","journal-title":"Neurobiol Dis"},{"key":"7970_CR58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA (2017) LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol Ther-Nucleic Acids 8:508\u2013519","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"32","key":"7970_CR59","doi-asserted-by":"crossref","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","volume":"290","author":"JP Daher","year":"2015","unstructured":"Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-synuclein gene-induced neurodegeneration. J Biol Chem 290(32):19433\u201319444","journal-title":"J Biol Chem"},{"issue":"2","key":"7970_CR60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pneurobio.2012.06.003","volume":"98","author":"G Wang","year":"2012","unstructured":"Wang G, Pan J, Chen S-D (2012) Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson\u2019s disease. Prog Neurobiol 98(2):207\u2013221","journal-title":"Prog Neurobiol"},{"issue":"1","key":"7970_CR61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"J-M Taymans","year":"2023","unstructured":"Taymans J-M, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, Peter I, Rideout H, Thaler A (2023) Perspective on the current state of the LRRK2 field. npj Parkinson\u2019s Disease 9(1):104","journal-title":"npj Parkinson's Disease"},{"key":"7970_CR62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fnins.2020.00577","volume":"14","author":"DM O\u2019Hara","year":"2020","unstructured":"O\u2019Hara DM, Pawar G, Kalia SK, Kalia LV (2020) LRRK2 and \u03b1-synuclein: distinct or synergistic players in Parkinson\u2019s disease? Front Neurosci 14:577","journal-title":"Front Neurosci"},{"issue":"1","key":"7970_CR63","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1038\/s41467-018-05958-z","volume":"9","author":"E-J Bae","year":"2018","unstructured":"Bae E-J, Kim D-K, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR (2018) LRRK2 kinase regulates \u03b1-synuclein propagation via RAB35 phosphorylation. Nat Commun 9(1):3465","journal-title":"Nat Commun"},{"issue":"1","key":"7970_CR64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13311-022-01290-z","volume":"20","author":"M Volta","year":"2023","unstructured":"Volta M (2023) Lysosomal Pathogenesis of Parkinson\u2019s Disease: Insights From LRRK2 and GBA1 Rodent Models. Neurotherapeutics 20(1):127\u2013139","journal-title":"Neurotherapeutics"},{"issue":"6824","key":"7970_CR65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","volume":"410","author":"L Chang","year":"2001","unstructured":"Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410(6824):37\u201340","journal-title":"Nature"},{"key":"7970_CR66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0074-7742(04)59008-6","volume":"59","author":"SV Kyosseva","year":"2004","unstructured":"Kyosseva SV (2004) Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59:201\u2013220","journal-title":"Int Rev Neurobiol"},{"issue":"5198","key":"7970_CR67","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7839144","volume":"267","author":"B D\u00e9rijard","year":"1995","unstructured":"D\u00e9rijard B, Raingeaud J, Barrett T, Wu I-H, Han J, Ulevitch RJ, Davis RJ (1995) Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267(5198):682\u2013685","journal-title":"Science"},{"issue":"3","key":"7970_CR68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.molcel.2005.04.001","volume":"18","author":"M Takekawa","year":"2005","unstructured":"Takekawa M, Tatebayashi K, Saito H (2005) Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell 18(3):295\u2013306","journal-title":"Mol Cell"},{"issue":"9","key":"7970_CR69","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrm906","volume":"3","author":"KA Gallo","year":"2002","unstructured":"Gallo KA, Johnson GL (2002) Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 3(9):663\u2013672","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"7970_CR70","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1471-4159.2010.06568.x","volume":"112","author":"CH Hsu","year":"2010","unstructured":"Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, Ferree A, Raghavan K, Shen GC, Segal L, Ryu H (2010) MKK6 binds and regulates expression of Parkinson\u2019s disease-related protein LRRK2. J Neurochem 112(6):1593\u20131604","journal-title":"J Neurochem"},{"issue":"10","key":"7970_CR71","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/cdd.2012.42","volume":"19","author":"C Chen","year":"2012","unstructured":"Chen C, Weng YH, Chien KY, Lin K, Yeh T, Cheng Y, Lu C, Wang H (2012) (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19(10):1623\u20131633","journal-title":"Cell Death Differ"},{"issue":"5","key":"7970_CR72","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cellsig.2010.01.006","volume":"22","author":"I Carballo-Carbajal","year":"2010","unstructured":"Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, Patenge N, Gasser T, Kahle PJ (2010) Leucine-rich repeat kinase 2 induces \u03b1-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal 22(5):821\u2013827","journal-title":"Cell Signal"},{"key":"7970_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-017-0737-y","volume":"17","author":"K Rosborough","year":"2017","unstructured":"Rosborough K, Patel N, Kalia LV (2017) \u03b1-Synuclein and parkinsonism: updates and future perspectives. Curr Neurol Neurosci Rep 17:1\u201311","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"7970_CR74","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/ijms23116216","volume":"23","author":"I Kawahata","year":"2022","unstructured":"Kawahata I, Finkelstein DI, Fukunaga K (2022) Pathogenic impact of \u03b1-synuclein phosphorylation and its kinases in \u03b1-synucleinopathies. Int J Mol Sci 23(11):6216","journal-title":"Int J Mol Sci"},{"issue":"LRRK2","key":"7970_CR75","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-49969-7_11","volume":"2","author":"JPL Daher","year":"2017","unstructured":"Daher JPL (2017) Interaction of LRRK2 and \u03b1-Synuclein in Parkinson\u2019s Disease. Leucine-rich Repeat Kinase 2(LRRK2):209\u2013226","journal-title":"Leucine-rich Repeat Kinase"},{"issue":"6","key":"7970_CR76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","volume":"64","author":"X Lin","year":"2009","unstructured":"Lin X, Parisiadou L, Gu X-L, Wang L, Shim H, Sun L, Xie C, Long C-X, Yang W-J, Ding J (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant \u03b1-synuclein. Neuron 64(6):807\u2013827","journal-title":"Neuron"},{"issue":"1","key":"7970_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-018-0454-0","volume":"25","author":"M-L Chen","year":"2018","unstructured":"Chen M-L, Wu R-M (2018) LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson\u2019s disease: a review. J Biomed Sci 25(1):52. https:\/\/doi.org\/10.1186\/s12929-018-0454-0","journal-title":"J Biomed Sci"},{"issue":"1","key":"7970_CR78","doi-asserted-by":"publisher","first-page":"7917128","DOI":"10.1155\/2016\/7917128","volume":"2016","author":"DH Ho","year":"2016","unstructured":"Ho DH, Jang J, Joe E-H, Son I, Seo H, Seol W (2016) G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. Biomed Res Int 2016(1):7917128. https:\/\/doi.org\/10.1155\/2016\/7917128","journal-title":"Biomed Res Int"},{"key":"7970_CR79","doi-asserted-by":"publisher","unstructured":"Wallings RL, Tansey MG (2019) LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Transact 47 (6), 1581-1595. https:\/\/doi.org\/10.1042\/bst20180463. Acccessed 12\/7\/2024","DOI":"10.1042\/bst20180463"},{"issue":"30","key":"7970_CR80","doi-asserted-by":"crossref","first-page":"46890","DOI":"10.18632\/oncotarget.10378","volume":"7","author":"H Zhao","year":"2016","unstructured":"Zhao H, Kong Z (2016) Relationship between LRRK2 R1628P polymorphism and Parkinson\u2019s disease in Asian populations. Oncotarget 7(30):46890","journal-title":"Oncotarget"},{"issue":"3","key":"7970_CR81","doi-asserted-by":"crossref","first-page":"e0149739","DOI":"10.1371\/journal.pone.0149739","volume":"11","author":"Y Shu","year":"2016","unstructured":"Shu Y, Ming J, Zhang P, Wang Q, Jiao F, Tian B (2016) Parkinson-related LRRK2 mutation R1628P enables Cdk5 phosphorylation of LRRK2 and upregulates its kinase activity. PLoS ONE 11(3):e0149739","journal-title":"PLoS ONE"},{"issue":"1","key":"7970_CR82","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"SY-Y Pang","year":"2022","unstructured":"Pang SY-Y, Lo RCN, Ho PW-L, Liu H-F, Chang EES, Leung C-T, Malki Y, Choi ZY-K, Wong WY, Kung MH-W et al (2022) LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener 11(1):5. https:\/\/doi.org\/10.1186\/s40035-022-00281-6","journal-title":"Transl Neurodegener"},{"issue":"10","key":"7970_CR83","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-019-01139-4","volume":"79","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Dzamko N (2019) Recent Developments in LRRK2-Targeted Therapy for Parkinson\u2019s Disease. Drugs 79(10):1037\u20131051. https:\/\/doi.org\/10.1007\/s40265-019-01139-4","journal-title":"Drugs"},{"key":"7970_CR84","first-page":"846","volume":"10","author":"AF Abdel-Magid","year":"2019","unstructured":"Abdel-Magid AF (2019) LRRK2 kinase inhibitors as possible therapy for Parkinson\u2019s disease and other neurodegenerative disorders. ACS Publications 10:846\u2013847","journal-title":"ACS Publications"},{"issue":"13","key":"7970_CR85","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4155\/fmc.12.110","volume":"4","author":"S Ray","year":"2012","unstructured":"Ray S, Liu M (2012) Current understanding of LRRK2 in Parkinson\u2019s disease: biochemical and structural features and inhibitor design. Future Med Chem 4(13):1701\u20131713","journal-title":"Future Med Chem"},{"issue":"9","key":"7970_CR86","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1089\/ars.2009.2430","volume":"11","author":"S Sen","year":"2009","unstructured":"Sen S, West AB (2009) The Therapeutic Potential of LRRK2 and \u03b1-Synuclein in Parkinson\u2019s Disease. Antioxid Redox Signal 11(9):2167\u20132187","journal-title":"Antioxid Redox Signal"},{"issue":"LRRK2","key":"7970_CR87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-319-49969-7_3","volume":"2","author":"RJ Nichols","year":"2017","unstructured":"Nichols RJ (2017) LRRK2 phosphorylation. Leucine-Rich Repeat Kinase 2(LRRK2):51\u201370","journal-title":"Leucine-Rich Repeat Kinase"},{"key":"7970_CR88","doi-asserted-by":"crossref","unstructured":"Myasnikov A, Zhu H, Hixson P, Xie B, Yu K, Pitre A, Peng J, Sun J (2021) Structural analysis of the full-length human LRRK2. Cell 184(13):3519\u20133527. e3510.","DOI":"10.1016\/j.cell.2021.05.004"},{"key":"7970_CR89","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1007\/s12035-014-8980-6","volume":"52","author":"A Esteves","year":"2015","unstructured":"Esteves A, G-fernandes M, Santos D, Janu\u00e1rio C, Cardoso S (2015) The upshot of LRRK2 inhibition to Parkinson\u2019s disease paradigm. Mol Neurobiol 52:1804\u20131820","journal-title":"Mol Neurobiol"},{"issue":"5","key":"7970_CR90","doi-asserted-by":"crossref","first-page":"e00660","DOI":"10.1128\/MCB.00660-20","volume":"41","author":"A Usmani","year":"2021","unstructured":"Usmani A, Shavarebi F, Hiniker A (2021) The cell biology of LRRK2 in Parkinson\u2019s disease. Mol Cell Biol 41(5):e00660-e620","journal-title":"Mol Cell Biol"},{"issue":"17","key":"7970_CR91","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1016\/j.bmcl.2012.06.104","volume":"22","author":"AD Reith","year":"2012","unstructured":"Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22(17):5625\u20135629","journal-title":"Bioorg Med Chem Lett"},{"key":"7970_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00441-8","volume":"16","author":"JH Kluss","year":"2021","unstructured":"Kluss JH, Mazza MC, Li Y, Manzoni C, Lewis PA, Cookson MR, Mamais A (2021) Preclinical modeling of chronic inhibition of the Parkinson\u2019s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener 16:1\u201319","journal-title":"Mol Neurodegener"},{"issue":"3","key":"7970_CR93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M (2005) A small molecule\u2013kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23(3):329\u2013336","journal-title":"Nat Biotechnol"},{"issue":"1","key":"7970_CR94","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26(1):127\u2013132","journal-title":"Nat Biotechnol"},{"issue":"10","key":"7970_CR95","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.stemcr.2022.09.001","volume":"17","author":"A Vuidel","year":"2022","unstructured":"Vuidel A, Cousin L, Weykopf B, Haupt S, Hanifehlou Z, Wiest-Daessl\u00e9 N, Segschneider M, Lee J, Kwon Y-J, Peitz M (2022) High-content phenotyping of Parkinson\u2019s disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification. Stem Cell Reports 17(10):2349\u20132364","journal-title":"Stem Cell Reports"},{"key":"7970_CR96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tox.2018.01.003","volume":"395","author":"MA Andersen","year":"2018","unstructured":"Andersen MA, Wegener KM, Larsen S, Badolo L, Smith GP, Jeggo R, Jensen PH, Sotty F, Christensen KV, Thougaard A (2018) PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology 395:15\u201322","journal-title":"Toxicology"},{"issue":"3","key":"7970_CR97","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","volume":"430","author":"N Dzamko","year":"2010","unstructured":"Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910\/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochemical Journal 430(3):405\u2013413","journal-title":"Biochemical Journal"},{"issue":"2","key":"7970_CR98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JPD-191786","volume":"10","author":"S Padmanabhan","year":"2020","unstructured":"Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, Lawrence-Henderson R, Levers N, Joshi N, Ma TC (2020) An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson\u2019s disease and G2019S LRRK2 cohorts. J Parkinsons Dis 10(2):623\u2013629","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"7970_CR99","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.538","volume":"7","author":"X Deng","year":"2011","unstructured":"Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee J-D, Patricelli MP, Nomanbhoy TK, Alessi DR (2011) Characterization of a selective inhibitor of the Parkinson\u2019s disease kinase LRRK2. Nat Chem Biol 7(4):203\u2013205","journal-title":"Nat Chem Biol"},{"issue":"8","key":"7970_CR100","doi-asserted-by":"crossref","first-page":"e1368","DOI":"10.1038\/cddis.2014.320","volume":"5","author":"S Saez-Atienzar","year":"2014","unstructured":"Saez-Atienzar S, Bonet-Ponce L, Blesa J, Romero F, Murphy M, Jordan J, Galindo M (2014) The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis 5(8):e1368\u2013e1368","journal-title":"Cell Death Dis"},{"issue":"1","key":"7970_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3(1):1\u201321","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"7970_CR102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.devcel.2007.11.019","volume":"14","author":"A Cassidy-Stone","year":"2008","unstructured":"Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR (2008) Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax\/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14(2):193\u2013204","journal-title":"Dev Cell"},{"issue":"7","key":"7970_CR103","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","volume":"93","author":"A Yoritaka","year":"1996","unstructured":"Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci 93(7):2696\u20132701","journal-title":"Proc Natl Acad Sci"},{"key":"7970_CR104","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1353-8020(09)70010-0","volume":"15","author":"N Hattori","year":"2009","unstructured":"Hattori N, Wang M, Taka H, Fujimura T, Yoritaka A, Kubo S-I, Mochizuki H (2009) Toxic effects of dopamine metabolism in Parkinson\u2019s disease. Parkinsonism Relat Disord 15:S35\u2013S38","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"7970_CR105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355(3):397\u2013409","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"7970_CR106","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archneurol.2010.79","volume":"67","author":"JC D\u00e4chsel","year":"2010","unstructured":"D\u00e4chsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67(5):542\u2013547","journal-title":"Arch Neurol"},{"issue":"1","key":"7970_CR107","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ncomms1453","volume":"2","author":"MJ Devine","year":"2011","unstructured":"Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman J-W (2011) Parkinson\u2019s disease induced pluripotent stem cells with triplication of the \u03b1-synuclein locus. Nat Commun 2(1):440","journal-title":"Nat Commun"},{"issue":"11","key":"7970_CR108","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/mds.23776","volume":"26","author":"K Gwinn","year":"2011","unstructured":"Gwinn K, Devine MJ, Jin L-W, Johnson J, Bird T, Muenter M, Waters C, Adler CH, Caselli R, Houlden H (2011) Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by \u03b1-synuclein triplication (Iowa kindred). Mov Disord: Off J Mov Disord Soc 26(11):2134","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"22","key":"7970_CR109","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","volume":"55","author":"AA Estrada","year":"2012","unstructured":"Estrada AA, Liu X, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chan BK, Chen H, Ding X, DiPasquale AG (2012) Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 55(22):9416\u20139433","journal-title":"J Med Chem"},{"key":"7970_CR110","unstructured":"Baptista M, Merchant K, Bharghava S, Bryce D, Ellis M, Estrada A, Fell M, Fuji R, Galatsis P, Hill S (2015) LRRK2 kinase inhibitors of different structural classes induce abnormal accumulation of lamellar bodies in type II pneumocytes in non-human primates but are reversible and without pulmonary functional consequences. In: 45th International Society for Neuroscience Meeting 763."},{"key":"7970_CR111","doi-asserted-by":"crossref","first-page":"954536","DOI":"10.3389\/fcell.2022.954536","volume":"10","author":"X Chen","year":"2022","unstructured":"Chen X, Wang Q, Li S, Li X-J, Yang W (2022) Mitochondrial-dependent and independent functions of PINK1. Front Cell Dev Biol 10:954536","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"7970_CR112","doi-asserted-by":"crossref","first-page":"e1004279","DOI":"10.1371\/journal.pgen.1004279","volume":"10","author":"RE Thomas","year":"2014","unstructured":"Thomas RE, Andrews LA, Burman JL, Lin W-Y, Pallanck LJ (2014) PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. PLoS Genet 10(5):e1004279","journal-title":"PLoS Genet"},{"key":"7970_CR113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ceb.2015.01.002","volume":"33","author":"A Eiyama","year":"2015","unstructured":"Eiyama A, Okamoto K (2015) PINK1\/Parkin-mediated mitophagy in mammalian cells. Curr Opin Cell Biol 33:95\u2013101","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"7970_CR114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-021-00888-x","volume":"13","author":"W Yang","year":"2022","unstructured":"Yang W, Guo X, Tu Z, Chen X, Han R, Liu Y, Yan S, Wang Q, Wang Z, Zhao X (2022) PINK1 kinase dysfunction triggers neurodegeneration in the primate brain without impacting mitochondrial homeostasis. Protein Cell 13(1):26\u201346","journal-title":"Protein Cell"},{"issue":"3","key":"7970_CR115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41419-019-1470-z","volume":"10","author":"N Yao","year":"2019","unstructured":"Yao N, Wang C, Hu N, Li Y, Liu M, Lei Y, Chen M, Chen L, Chen C, Lan P (2019) Inhibition of PINK1\/Parkin-dependent mitophagy sensitizes multidrug-resistant cancer cells to B5G1, a new betulinic acid analog. Cell Death Dis 10(3):232","journal-title":"Cell Death Dis"},{"key":"7970_CR116","first-page":"139","volume-title":"Mitophagy","author":"L King","year":"2017","unstructured":"King L, Plun-Favreau H (2017) Mitophagy. Elsevier, In Parkinson\u2019s Disease, pp 139\u2013177"},{"issue":"9","key":"7970_CR117","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41556-018-0176-2","volume":"20","author":"K Palikaras","year":"2018","unstructured":"Palikaras K, Lionaki E, Tavernarakis N (2018) Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol 20(9):1013\u20131022","journal-title":"Nat Cell Biol"},{"issue":"7097","key":"7970_CR118","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nature04788","volume":"441","author":"J Park","year":"2006","unstructured":"Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim J-M (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441(7097):1157\u20131161","journal-title":"Nature"},{"issue":"33","key":"7970_CR119","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1038\/sj.onc.1204608","volume":"20","author":"M Unoki","year":"2001","unstructured":"Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20(33):4457\u20134465","journal-title":"Oncogene"},{"issue":"4","key":"7970_CR120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ejn.14264","volume":"49","author":"A Bose","year":"2019","unstructured":"Bose A, Beal MF (2019) Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson\u2019s disease. Eur J Neurosci 49(4):525\u2013532","journal-title":"Eur J Neurosci"},{"issue":"8","key":"7970_CR121","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/biomedicines9080918","volume":"9","author":"H-C Kung","year":"2021","unstructured":"Kung H-C, Lin K-J, Kung C-T, Lin T-K (2021) Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson\u2019s disease. Biomedicines 9(8):918","journal-title":"Biomedicines"},{"issue":"1","key":"7970_CR122","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.2003.tb07470.x","volume":"991","author":"MF Beal","year":"2003","unstructured":"Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson\u2019s disease. Ann N Y Acad Sci 991(1):120\u2013131","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"7970_CR123","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/antiox9080647","volume":"9","author":"A Picca","year":"2020","unstructured":"Picca A, Calvani R, Coelho-Junior HJ, Landi F, Bernabei R, Marzetti E (2020) Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration. Antioxidants 9(8):647","journal-title":"Antioxidants"},{"issue":"7","key":"7970_CR124","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1139\/cjpp-2014-0060","volume":"92","author":"S Givvimani","year":"2014","unstructured":"Givvimani S, Pushpakumar S, Veeranki S, Tyagi SC (2014) Dysregulation of Mfn2 and Drp-1 proteins in heart failure. Can J Physiol Pharmacol 92(7):583\u2013591","journal-title":"Can J Physiol Pharmacol"},{"issue":"3","key":"7970_CR125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuron.2005.06.018","volume":"47","author":"P Verstreken","year":"2005","unstructured":"Verstreken P, Ly CV, Venken KJ, Koh T-W, Zhou Y, Bellen HJ (2005) Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 47(3):365\u2013378","journal-title":"Neuron"},{"issue":"3","key":"7970_CR126","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuron.2005.07.017","volume":"47","author":"PJ Hollenbeck","year":"2005","unstructured":"Hollenbeck PJ (2005) Mitochondria and neurotransmission: evacuating the synapse. Neuron 47(3):331\u2013333","journal-title":"Neuron"},{"issue":"7","key":"7970_CR127","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1523\/JNEUROSCI.1316-20.2020","volume":"41","author":"A Mandal","year":"2021","unstructured":"Mandal A, Wong H-TC, Pinter K, Mosqueda N, Beirl A, Lomash RM, Won S, Kindt KS, Drerup CM (2021) Retrograde mitochondrial transport is essential for organelle distribution and health in zebrafish neurons. J Neurosci 41(7):1371\u20131392","journal-title":"J Neurosci"},{"issue":"1","key":"7970_CR128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1601-183X.2006.00218.x","volume":"6","author":"R Rikhy","year":"2007","unstructured":"Rikhy R, Kamat S, Ramagiri S, Sriram V, Krishnan K (2007) Mutations in dynamin-related protein result in gross changes in mitochondrial morphology and affect synaptic vesicle recycling at the Drosophila neuromuscular junction. Genes Brain Behav 6(1):42\u201353","journal-title":"Genes Brain Behav"},{"issue":"4","key":"7970_CR129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/1073858406287661","volume":"12","author":"CV Ly","year":"2006","unstructured":"Ly CV, Verstreken P (2006) Mitochondria at the synapse. Neuroscientist 12(4):291\u2013299","journal-title":"Neuroscientist"},{"issue":"14","key":"7970_CR130","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"L Devi","year":"2008","unstructured":"Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of \u03b1-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283(14):9089\u20139100","journal-title":"J Biol Chem"},{"issue":"7","key":"7970_CR131","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2(7):492\u2013501","journal-title":"Nat Rev Neurosci"},{"key":"7970_CR132","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2019.04.029","volume":"705","author":"S Miller","year":"2019","unstructured":"Miller S, Muqit MM (2019) Therapeutic approaches to enhance PINK1\/Parkin mediated mitophagy for the treatment of Parkinson\u2019s disease. Neurosci Lett 705:7\u201313","journal-title":"Neurosci Lett"},{"key":"7970_CR133","doi-asserted-by":"crossref","first-page":"890823","DOI":"10.3389\/fnagi.2022.890823","volume":"14","author":"LF Silvian","year":"2022","unstructured":"Silvian LF (2022) PINK1\/Parkin Pathway Activation for Mitochondrial Quality Control-Which Is the Best Molecular Target for Therapy? Frontiers in aging neuroscience 14:890823","journal-title":"Frontiers in aging neuroscience"},{"issue":"6","key":"7970_CR134","doi-asserted-by":"crossref","first-page":"e3002196","DOI":"10.1371\/journal.pbio.3002196","volume":"21","author":"B O\u2019Callaghan","year":"2023","unstructured":"O\u2019Callaghan B, Hardy J, Plun-Favreau H (2023) PINK1: From Parkinson\u2019s disease to mitophagy and back again. PLoS Biol 21(6):e3002196","journal-title":"PLoS Biol"},{"issue":"9","key":"7970_CR135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41416-020-0778-x","volume":"122","author":"W Dai","year":"2020","unstructured":"Dai W, Wang G, Chwa J, Oh ME, Abeywardana T, Yang Y, Wang QA, Jiang L (2020) Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer. Br J Cancer 122(9):1288\u20131297","journal-title":"Br J Cancer"},{"issue":"2","key":"7970_CR136","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1083\/jcb.200910140","volume":"189","author":"N Matsuda","year":"2010","unstructured":"Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou Y-S, Saiki S, Kawajiri S, Sato F (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189(2):211\u2013221","journal-title":"J Cell Biol"},{"issue":"1","key":"7970_CR137","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1038\/s41467-023-42876-1","volume":"14","author":"T-SZ Fang","year":"2023","unstructured":"Fang T-SZ, Sun Y, Pearce AC, Eleuteri S, Kemp M, Luckhurst CA, Williams R, Mills R, Almond S, Burzynski L (2023) Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson\u2019s disease mouse model. Nat Commun 14(1):7295","journal-title":"Nat Commun"},{"issue":"4","key":"7970_CR138","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1074\/jbc.M507943200","volume":"281","author":"K Naylor","year":"2006","unstructured":"Naylor K, Ingerman E, Okreglak V, Marino M, Hinshaw JE, Nunnari J (2006) Mdv1 interacts with assembled dnm1 to promote mitochondrial division. J Biol Chem 281(4):2177\u20132183","journal-title":"J Biol Chem"},{"issue":"1","key":"7970_CR139","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1534-5807(01)00116-2","volume":"2","author":"L Scorrano","year":"2002","unstructured":"Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA, Korsmeyer SJ (2002) A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell 2(1):55\u201367","journal-title":"Dev Cell"},{"issue":"5","key":"7970_CR140","doi-asserted-by":"crossref","first-page":"120080","DOI":"10.1098\/rsob.120080","volume":"2","author":"C Kondapalli","year":"2012","unstructured":"Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2(5):120080","journal-title":"Open Biol"},{"issue":"3","key":"7970_CR141","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.bbrc.2008.10.104","volume":"377","author":"Y Kim","year":"2008","unstructured":"Kim Y, Park J, Kim S, Song S, Kwon S-K, Lee S-H, Kitada T, Kim J-M, Chung J (2008) PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 377(3):975\u2013980","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"7970_CR142","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1042\/BCJ20210508","volume":"478","author":"E Tsefou","year":"2021","unstructured":"Tsefou E, Walker AS, Clark EH, Hicks AR, Luft C, Takeda K, Watanabe T, Ramazio B, Staddon JM, Briston T (2021) Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches. Biochem J 478(23):4099\u20134118","journal-title":"Biochem J"},{"key":"7970_CR143","doi-asserted-by":"crossref","first-page":"851654","DOI":"10.3389\/fphar.2022.851654","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Gao Y, Zhou L, Chen J, Xie Z, Ye Z, Wang Y (2022) USP30: structure, emerging physiological role, and target inhibition. Front Pharmacol 13:851654","journal-title":"Front Pharmacol"},{"issue":"8","key":"7970_CR144","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1021\/jm501759m","volume":"58","author":"S Kovackova","year":"2015","unstructured":"Kovackova S, Chang L, Bekerman E, Neveu G, Barouch-Bentov R, Chaikuad A, Heroven C, \u0160\u00e1la M, De Jonghe S, Knapp S (2015) Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis C agents. J Med Chem 58(8):3393\u20133410","journal-title":"J Med Chem"},{"issue":"1","key":"7970_CR145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-5793(96)01484-6","volume":"402","author":"Y Kanaoka","year":"1997","unstructured":"Kanaoka Y, Kimura SH, Okazaki I, Ikeda M, Nojima H (1997) GAK: a cyclin G associated kinase contains a tensin\/auxilin-like domain 1. FEBS Lett 402(1):73\u201380","journal-title":"FEBS Lett"},{"issue":"1","key":"7970_CR146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P (2023) Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):73","journal-title":"Signal Transduct Target Ther"},{"key":"7970_CR147","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00412-010-0267-8","volume":"119","author":"ME Tanenbaum","year":"2010","unstructured":"Tanenbaum ME, Vallenius T, Geers EF, Greene L, M\u00e4kel\u00e4 TP, Medema RH (2010) Cyclin G-associated kinase promotes microtubule outgrowth from chromosomes during spindle assembly. Chromosoma 119:415\u2013424","journal-title":"Chromosoma"},{"issue":"6557","key":"7970_CR148","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/378632a0","volume":"378","author":"E Ungewickell","year":"1995","unstructured":"Ungewickell E, Ungewickell H, Holstein SEH, Lindner R, Prasad K, Barouch W, Martini B, Greene LE, Eisenberg E (1995) Role of auxilin in uncoating clathrin-coated vesicles. Nature 378(6557):632\u2013635. https:\/\/doi.org\/10.1038\/378632a0","journal-title":"Nature"},{"issue":"2","key":"7970_CR149","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1074\/jbc.275.2.1365","volume":"275","author":"T Greener","year":"2000","unstructured":"Greener T, Zhao X, Nojima H, Eisenberg E, Greene LE (2000) Role of cyclin G-associated kinase in uncoating clathrin-coated vesicles from non-neuronal cells. J Biol Chem 275(2):1365\u20131370","journal-title":"J Biol Chem"},{"issue":"8","key":"7970_CR150","doi-asserted-by":"crossref","first-page":"e0160925","DOI":"10.1371\/journal.pone.0160925","volume":"11","author":"MW Nagle","year":"2016","unstructured":"Nagle MW, Latourelle JC, Labadorf A, Dumitriu A, Hadzi TC, Beach TG, Myers RH (2016) The 4p16. 3 Parkinson disease risk locus is associated with GAK expression and genes involved with the synaptic vesicle membrane. PloS one 11(8):e0160925","journal-title":"PloS one"},{"key":"7970_CR151","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00439-008-0582-9","volume":"124","author":"N Pankratz","year":"2009","unstructured":"Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124:593\u2013605","journal-title":"Hum Genet"},{"issue":"6","key":"7970_CR152","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ejhg.2010.254","volume":"19","author":"J Sim\u00f3n-S\u00e1nchez","year":"2011","unstructured":"Sim\u00f3n-S\u00e1nchez J, Van Hilten JJ, Van De Warrenburg B, Post B, Berendse HW, Arepalli S, Hernandez DG, de Bie R, Velseboer D, Scheffer H (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 19(6):655\u2013661","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"7970_CR153","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet 46(9):989\u2013993","journal-title":"Nat Genet"},{"issue":"1","key":"7970_CR154","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D (2018) The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep 8(1):16165","journal-title":"Sci Rep"},{"issue":"2","key":"7970_CR155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D (2017) \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23(2):1\u201313","journal-title":"Nat Med"},{"issue":"1","key":"7970_CR156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T (2011) Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1\u201311","journal-title":"Chem Biol Drug Des"},{"key":"7970_CR157","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s002510000270","volume":"52","author":"S Chida","year":"2001","unstructured":"Chida S, Hohjoh H, Hirai M, Tokunaga K (2001) Haplotype-specific sequence encoding the protein kinase, interferon-inducible double-stranded RNA-dependent activator in the human leukocyte antigen class II region. Immunogenetics 52:186\u2013194","journal-title":"Immunogenetics"},{"issue":"5","key":"7970_CR158","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mds.26583","volume":"31","author":"M Quadri","year":"2016","unstructured":"Quadri M, Olgiati S, Sensi M, Gualandi F, Groppo E, Rispoli V, Graafland J, Breedveld GJ, Fabbrini G, Berardelli A (2016) PRKRA mutation causing early-onset generalized dystonia-parkinsonism (DYT16) in an Italian family. Mov Disord 31(5):765\u2013767","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07970-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07970-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07970-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:50:14Z","timestamp":1742320214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07970-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7970"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07970-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article does not involve any studies with human participants or animals performed by any of the authors. As this is a literature-based review, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}